Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423878 · ClinicalTrials.gov registry record · Phase 4
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
A Phase 4 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 215
- Enrollment target
NCT00423878 is a Phase 4 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 215 participants.
The verdict
NCT00423878, a Phase 4 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 215 participants
- Enrollment target
Study Summary
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423878
The ClinicalTrials.gov registry entry for NCT00423878 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Risperidone is the first listed.
NCT00423878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423878 about?
NCT00423878 is a clinical study titled "Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder". The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.
What is the current status of trial NCT00423878?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 215 participants. The study started on 2007-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00423878?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00423878?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.